SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Cannabis >

Nemus Bioscience, Inc. (NMUS)

NMUS RSS Feed
Add NMUS Price Alert      Hide Sticky   Hide Intro
Moderator: Paulieme, goodibag
Search This Board: 
Last Post: 12/14/2017 10:07:52 PM - Followers: 107 - Board type: Free - Posts Today: 0


 

 NEMUS BIOSCIENCE™ provides pharmaceutical research and development services focused on discovering, developing, and commercializing new chemical entities from a class of chemically diverse compounds. We develop novel and proprietary classes of product candidates that are designed to improve therapeutic options through enhanced chemical engineering that allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.

NEMUS Bioscience Inc., a Nevada corporation, is a SEC fully reporting company listed on the  under the symbol NMUS.

Company Website:  http://www.nemusbioscience.com/home.html

Filings and disclosure with Level 2 quotes:  http://www.otcmarkets.com/stock/NMUS/quote

Contact:

(949) 396-0330
E-MAIL: BRIAN@NEMUSBIO.COM
600 ANTON BLVD, SUITE 1100, COSTA MESA, CA 92626


 

Nemus Bioscience (NMUS) Presentation (47 minutes):  
https://www.youtube.com/watch?v=tYV2PEaj6os

Presentation at the 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 12th, 2016: 
http://s2.q4cdn.com/753474459/files/doc_presentations/2016/Rodman-Conf-September-2016_FINAL.pdf



 


Major press releases:

A Sit Down With Nemus Bioscience; Cannabinoids In Focus Feb. 1, 2017 11:06 AM ET Nemus Bioscience, Inc. (NMUS)  
 

Nemus Bioscience Announces Milestones in the Development of Fully Synthetic Clinical-Grade Active Pharmaceutical Ingredient (API) for Drug Candidates NB1111 and NB2111 and Formulation Contract with AMRI and Catalent Pharma Solutions -


Cannabinoid Drug Advancements Take Off After Quantum Shift in U.S. Drug Policy


Nemus Bioscience Announces Presentation of NB1111 Impact on Intraocular Pressure (IOP) in Normotensive Ocular Model at the National Meeting of the American Association of Pharmaceutical Scientists (AAPS)

 

Nemus Bioscience Announces Enhanced Ocular Tissue Concentration by the Proprietary Prodrug of Tetrahydrocannabinol (NB1111) - Associated With a Superior Decline in Intra-Ocular Pressure (IOP) in an Animal Model

 

Nemus Bioscience, Inc. Announces Letter of Intent to License Biosynthetic Technology to Manufacture Its Proprietary Cannabinoid Molecules From Teewinot Life Sciences Corp.


NEMUS Bioscience Identifies Unique Cannabidiol (CBD) Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program 


CANNAINVESTOR Magazine Top 20 Cannabis Stocks 

 

NEMUS Bioscience CEO to Present at the 28th Annual ROTH Conference 

 

NEMUS Bioscience, Inc. Signs Agreement With Albany Molecular Research Inc. (AMRI) to Manufacture Cannabinoid-Based Active Pharmaceutical Ingredients 

 

NEMUS Bioscience Prodrug of THC (NB1111) Completes Validation Stage of Glaucoma Testing and Development 

 

Nemus Enters Into Research Agreement With the University of Mississippi to Develop Cannabinoid-Based Therapies for Chemotherapy-Induced Peripheral Neuropathy (CIPN) 

 

NMUS Security Details

Share Structure - as of Feb 1, 2017
Source: otcmarkets.com

Authorized Shares: 236,000,000
Outstanding Shares: 
22,438,163
      - Restricted  13,494,621
    - Unrestricted   8,943,542

           - Float   5,005,713 a/o Mar 23, 2016 
   Par Value 0.001


Transfer Agent: Clear Trust, LLC

SureTrader
Interactive Brokers Advertisement
NMUS
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NMUS News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 12/05/2017 06:06:38 AM
NMUS News: Notice of Effectiveness (effect) 12/05/2017 06:04:04 AM
NMUS News: Securities Registration Statement (s-1) 11/22/2017 05:01:42 PM
NMUS News: Quarterly Report (10-q) 11/14/2017 05:06:39 PM
NMUS News: Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) 11/14/2017 04:53:12 PM
PostSubject
#2993  Sticky Note 2018 is for MMJ Biotech Companies goodibag 12/10/17 11:56:14 PM
#2998   $NMUS Daily and Weekly Charts http://www.stock $Pistol Pete$ 12/14/17 10:07:52 PM
#2997   NMUS Presentation goodibag 12/11/17 12:20:21 AM
#2996   NMUS goodibag 12/10/17 11:59:29 PM
#2995   NMUS is working with Univ. of MISSISSIPPI goodibag 12/10/17 11:59:19 PM
#2994   NMUS is in the early stages of Research goodibag 12/10/17 11:57:33 PM
#2993   2018 is for MMJ Biotech Companies goodibag 12/10/17 11:56:14 PM
#2992   It's going to need a lot more than retired early 12/07/17 09:57:25 PM
#2991   My TD app is glitched and showing nemus Jdanger 2 12/07/17 12:31:56 PM
#2990   Lots of volume today Jdanger 2 12/07/17 12:08:56 PM
#2989   Nobody is doing themselves any favors by being Djdjdjdj 12/07/17 01:46:15 AM
#2988   Hmmm... Vinpat said the stock price spike in late AntonChigurh 12/06/17 01:58:09 PM
#2987   How many 424b3 to close a financing? Just come AntonChigurh 12/05/17 06:42:25 PM
#2986   August 21, 2015 NEMUS Bioscience Announces Closing of AntonChigurh 11/30/17 09:43:34 AM
#2985   New 52 week Low Has the financing closed? AntonChigurh 11/28/17 02:35:08 PM
#2984   I don't think I will even need to AntonChigurh 11/28/17 11:29:08 AM
#2983   I had no idea about Lykos getting a AntonChigurh 11/22/17 05:26:00 PM
#2982   I very much doubt that "Anton", but I cjarmstrong 11/22/17 05:17:44 PM
#2981   I knew about The loan but did not AntonChigurh 11/22/17 05:03:13 PM
#2980   Since it doesn't look like you will go cjarmstrong 11/22/17 05:00:47 PM
#2979   Presumably you knew this before you sold, while cjarmstrong 11/22/17 04:53:12 PM
#2978   Lykos devoting The majority of his Time to AntonChigurh 11/22/17 04:16:52 PM
#2977   Not only are they working on contingency, but cjarmstrong 11/22/17 12:00:03 PM
#2976   This is the last time I'll respond to Vinpat 11/22/17 11:39:49 AM
#2975   Vinpat says 'Doug Ingram is involved day-to-day' AntonChigurh 11/21/17 11:05:56 PM
#2974   Having said that, Elsohly developed the transmucosal patch cjarmstrong 11/17/17 12:33:57 PM
#2973   I said old news, but that I didn't cjarmstrong 11/16/17 09:56:05 AM
#2972   It was Insys and No one hear new AntonChigurh 11/15/17 10:07:01 PM
#2971   Old news. I posted that there was a cjarmstrong 11/15/17 06:51:23 PM
#2970   https://www.counterpunch.org/2009/01/16/growing-pot-for-research/ JANUARY 16, 2009 AntonChigurh 11/15/17 05:32:56 PM
#2969   The simplest explanation is most often the correct one. dary4321 11/14/17 04:19:42 PM
#2968   You don't get involved with Bad guys like AntonChigurh 11/14/17 12:05:02 PM
#2967   That is precisely what I did June 12th marctabar 11/14/17 05:20:32 AM
#2966   What does your good friend Vinpat have to cjarmstrong 11/14/17 12:38:21 AM
#2965   I think he probably has AntonChigurh 11/13/17 11:14:36 PM
#2964   So why are you guys holding this company dary4321 11/13/17 10:42:52 PM
#2963   Why didn't you report them to a regulatory cjarmstrong 11/13/17 10:19:23 PM
#2962   regarding Schneider, I worked for them as the marctabar 11/13/17 10:08:33 PM
#2961   Is "fake news" something people call other people? cjarmstrong 11/13/17 09:53:56 PM
#2960   Financial guarantee: Schneider leaves its customers in the AntonChigurh 11/13/17 07:18:44 PM
#2959   What? cjarmstrong 11/13/17 04:58:48 PM
#2958   Did you just call me Fake News, CJ? AntonChigurh 11/13/17 04:51:57 PM
#2957   The officer of the shell is irrelevant, he's cjarmstrong 11/13/17 04:50:31 PM
#2956   I am just Really excited for it, that's AntonChigurh 11/13/17 02:01:37 PM
#2955   Are you suggesting that they're late on their Vinpat 11/13/17 01:41:36 PM
#2954   Maybe Schneider can pay Nemus 10 million Ubiquicoin AntonChigurh 11/13/17 12:55:27 PM
#2953   However, we can reasonably argue that he (John marctabar 11/13/17 10:41:16 AM
#2952   Where is the 8K filing for the last AntonChigurh 11/10/17 05:31:49 PM
#2951   LOL Closewatcher 11/09/17 06:23:03 PM
#2950   That's fine but what does that have to Vinpat 11/09/17 04:48:04 PM
#2949   This is going to be fun GLTFA AntonChigurh 11/09/17 04:43:21 PM
PostSubject